What does PHARMFLY do?

PHARMFLY is registered with the CBE as active in: Handel in eigen onroerend goed. Private Limited, started on 18 April 1996, 1 establishment.

What is the address of PHARMFLY?

The registered office of PHARMFLY is located at Doorniksesteenweg 22, 8580 Avelgem.

Is PHARMFLY still active?

Yes. According to the CBE (29 October 2026) PHARMFLY is active, legal situation “Normale toestand”, started on 18 April 1996.

Is PHARMFLY registered on Peppol?

Yes, PHARMFLY is registered on the Peppol network with ID 0208:0457836931.

What is the enterprise number of PHARMFLY?

The enterprise number of PHARMFLY is BE0457836931.

When was PHARMFLY founded?

PHARMFLY was founded on 18 April 1996.

Who are the directors of PHARMFLY?

According to the 2025 annual accounts, the directors of PHARMFLY are: Erwin Rombaut.

Is PHARMFLY a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 April 1996; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMFLY make in 2025?

PHARMFLY posted a profit after taxes of € 23,116 in financial year 2025.

What is the revenue of PHARMFLY?

As a small company, PHARMFLY is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 32,018.

PHARMFLY (Private Limited) - Avelgem - BE0457836931

Dossier PHARMFLY, printed on 29 October 2026 from databakkes.be/en/0457836931/pharmfly. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 25 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMFLY from Avelgem, company number BE0457836931, closed financial year 2025 with a result of € 23,116 after tax. For that financial year PHARMFLY recorded a gross margin of € 32,018 and equity of € -18,869. Compared with financial year 2024, the result moved from € 15,672 to € 23,116. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 29, 2026.

What it is worth Caution

€ -18,869

▲ € 23,116 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 23,116

▲ 47% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 4,329

▲ 131% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -50,169.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 5,179

▲ 76% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 2,939

▲ 15% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 43,910 Gross margin 2022: € 43,910 First fiscal year in the series	€ 29,415 Gross margin 2023: € 29,415 ▼ 33% vs 2022 (€ 43,910) Unfavourable step	€ 24,487 Gross margin 2024: € 24,487 ▼ 17% vs 2023 (€ 29,415) Unfavourable step	€ 32,018 Gross margin 2025: € 32,018 ▲ 31% vs 2024 (€ 24,487) Favourable step	▲ 31%
Profit after taxes	€ 14,853 Profit after taxes 2022: € 14,853 First fiscal year in the series	€ 20,519 Profit after taxes 2023: € 20,519 ▲ 38% vs 2022 (€ 14,853) Favourable step	€ 15,672 Profit after taxes 2024: € 15,672 ▼ 24% vs 2023 (€ 20,519) Unfavourable step	€ 23,116 Profit after taxes 2025: € 23,116 ▲ 47% vs 2024 (€ 15,672) Favourable step	▲ 47%
Equity	€ -78,176 Equity 2022: € -78,176 First fiscal year in the series	€ -57,657 Equity 2023: € -57,657 ▲ € 20,519 vs 2022 (€ -78,176) Favourable step	€ -41,985 Equity 2024: € -41,985 ▲ € 15,672 vs 2023 (€ -57,657) Favourable step	€ -18,869 Equity 2025: € -18,869 ▲ € 23,116 vs 2024 (€ -41,985) Favourable step	▲ € 23,116
Total debts	€ 117,120 Total debts 2022: € 117,120 First fiscal year in the series	€ 97,463 Total debts 2023: € 97,463 ▼ 17% vs 2022 (€ 117,120) Favourable step	€ 81,655 Total debts 2024: € 81,655 ▼ 16% vs 2023 (€ 97,463) Favourable step	€ 72,453 Total debts 2025: € 72,453 ▼ 11% vs 2024 (€ 81,655) Favourable step	▼ 11%
Cash	€ 3,126 Cash 2022: € 3,126 First fiscal year in the series	€ 13,636 Cash 2023: € 13,636 ▲ € 10,509 vs 2022 (€ 3,126) Favourable step	€ 1,871 Cash 2024: € 1,871 ▼ 86% vs 2023 (€ 13,636) Unfavourable step	€ 4,329 Cash 2025: € 4,329 ▲ 131% vs 2024 (€ 1,871) Favourable step	▲ 131%
Land & buildings	€ 3,328 Land & buildings 2022: € 3,328 First fiscal year in the series	€ 1,130 Land & buildings 2023: € 1,130 ▼ 66% vs 2022 (€ 3,328) Unchanged	€ 389 Land & buildings 2024: € 389 ▼ 66% vs 2023 (€ 1,130) Unchanged	€ 7,380 Land & buildings 2025: € 7,380 ▲ € 6,991 vs 2024 (€ 389) Unchanged	▲ € 6,991
Retained profit	€ -112,606 Retained profit 2022: € -112,606 First fiscal year in the series	€ -92,087 Retained profit 2023: € -92,087 ▲ € 20,519 vs 2022 (€ -112,606) Favourable step	€ -76,415 Retained profit 2024: € -76,415 ▲ € 15,672 vs 2023 (€ -92,087) Favourable step	€ -50,169 Retained profit 2025: € -50,169 ▲ € 26,246 vs 2024 (€ -76,415) Favourable step	▲ € 26,246
Balance sheet total	€ 38,944 Balance sheet total 2022: € 38,944 First fiscal year in the series	€ 39,806 Balance sheet total 2023: € 39,806 ▲ 2% vs 2022 (€ 38,944) Unchanged	€ 39,670 Balance sheet total 2024: € 39,670 Unchanged (€ 39,806) Unchanged	€ 53,584 Balance sheet total 2025: € 53,584 ▲ 35% vs 2024 (€ 39,670) Unchanged	▲ 35%

Key figures of PHARMFLY, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to PHARMFLY?

What happened at PHARMFLY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 29, 2026 New annual accounts for financial year 2025: profit of € 23,116 (▲ 47% vs 2024). Source: NBB ↗
Nov 19, 2002 New establishment in Avelgem. KBO
Apr 18, 1996 Start of the company according to the CBE. KBO

In short

From € 14,853 profit in 2022 to € 23,116 profit in 2025.

Paid € 612 in corporate taxes since 2022.

Best year ever: 2025, with € 23,116 profit.

Original PDFs at the National Bank ↗

Management

Erwin Rombaut

PHARMFLY

SENSA TRAVEL

Behind PHARMFLY is Erwin Rombaut. Erwin Rombaut is also behind SENSA TRAVEL.

Directors

According to the 2025 annual accounts

Erwin Rombaut

Director

Also active at: SENSA TRAVEL

Establishments

Establishment units

Physical locations of this company

Registered office

Doorniksesteenweg 22

8580 Avelgem

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Apotheek Kempinaire

€ 76,074 gross margin · 2025

E.R.C.

€ 60,871 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0457.836.931

VAT number

BE 0457.836.931

Registered office

Doorniksesteenweg 22, 8580 Avelgem

Names & denominations

PHARMFLY

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

18 April 1996

Peppol

Active · Active since 9 Dec 2025

Activities · NACE

Handel in eigen onroerend goed

Handel in onroerend goed

Verhuur en lease van personenauto’s en andere lichte motorvoertuigen

Personenvervoer over de weg zonder dienstregeling

Organisatie van congressen en beurzen

Verhuur van auto's

Overig vervoer van personen te land

Organisatie van salons, tentoonstellingen en beurzen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMFLY

Warning lights

Financials

What happened to PHARMFLY?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions